Literature DB >> 33346666

Uptake and Transport of Ultrafine Nanoparticles (Quantum Dots) in the Nasal Mucosa.

Bhanu C Bejgum1, Maureen D Donovan1.   

Abstract

A wide variety of colloidal delivery systems, including polymeric nanoparticles, metal colloids, liposomes, and microemulsions have been reported to enhance the delivery of therapeutic agents across the nasal mucosa. The mechanisms involved in the uptake of these nanomaterials, especially ultrafine nanomaterials (diameters < 20 nm) through the nasal mucosa are not well understood. Fluorescent quantum dots (QDs) were used to investigate the uptake of ultrafine nanoparticles by bovine respiratory and olfactory mucosal tissues following in vitro exposure, and an inductively coupled plasma optical emission spectroscopy method was developed to quantify the amount of QDs localized within the tissues. QDs do not biodegrade or release their core materials and, as a result, this method allowed for the direct quantification of the nanoparticles themselves, rather than the measurement of a potentially dissociated drug or label. The results demonstrated that carboxylate-modified QDs (COOH-QDs) showed ∼2.5-fold greater accumulation in the epithelial and submucosal regions of olfactory tissues compared to that in respiratory tissues. Endocytic inhibitory studies showed that clathrin-dependent endocytosis, macropinocytosis, and caveolae-dependent endocytic process are all involved in the uptake of COOH-QDs into the respiratory tissues. In olfactory tissues, clathrin-dependent endocytosis is the major endocytic pathway involved in the uptake of COOH-QDs. Additional energy-independent pathways also appeared to allow the transfer of COOH-QDs within the olfactory mucosa. When polyethylene glycol-modified QDs known as PEGylated QDs (PEG-QDs) of similar size, ∼15 nm, were investigated, no nanoparticles were detected in the tissues suggesting that the PEG corona limits the interactions with endocytic and other uptake processes in the nasal epithelium. The capacity for nanoparticle uptake observed in the nasal mucosa, along with the ability of significant numbers of nanoparticles to enter the olfactory tissues using nonenergy-dependent pathways show that the pathways for ultrafine nanoparticle uptake in the nasal tissues have both drug delivery and toxicologic consequences. This places an increased importance on the careful selection of nanoparticle components and drugs intended for intranasal administration.

Entities:  

Keywords:  PEGylated nanoparticles; caveolae-dependent endocytosis; clathrin-dependent endocytosis; endocytosis; macropinocytosis; nanoparticles; nasal drug delivery; nasal respiratory mucosa; olfactory mucosa; quantum dots

Year:  2020        PMID: 33346666     DOI: 10.1021/acs.molpharmaceut.0c01074

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  Intracellular Trafficking and Distribution of Cd and InP Quantum Dots in HeLa and ML-1 Thyroid Cancer Cells.

Authors:  Min Zhang; Daniel S Kim; Rishi Patel; Qihua Wu; Kyoungtae Kim
Journal:  Nanomaterials (Basel)       Date:  2022-04-29       Impact factor: 5.719

Review 2.  Different Methods and Formulations of Drugs and Vaccines for Nasal Administration.

Authors:  Junhu Tai; Munsoo Han; Dabin Lee; Il-Ho Park; Sang Hag Lee; Tae Hoon Kim
Journal:  Pharmaceutics       Date:  2022-05-17       Impact factor: 6.525

3.  CdSe/ZnS Core-Shell-Type Quantum Dot Nanoparticles Disrupt the Cellular Homeostasis in Cellular Blood-Brain Barrier Models.

Authors:  Katarzyna Dominika Kania; Waldemar Wagner; Łukasz Pułaski
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

4.  Fabrication of Smart Tantalum Carbide MXene Quantum Dots with Intrinsic Immunomodulatory Properties for Treatment of Allograft Vasculopathy.

Authors:  Alireza Rafieerad; Weiang Yan; Keshav Narayan Alagarsamy; Abhay Srivastava; Niketa Sareen; Rakesh C Arora; Sanjiv Dhingra
Journal:  Adv Funct Mater       Date:  2021-09-08       Impact factor: 18.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.